Northern Trust Corp Has $22.83 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Northern Trust Corp grew its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 1,822.1% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,445,572 shares of the company's stock after buying an additional 1,370,366 shares during the period. Northern Trust Corp owned approximately 0.17% of Dr. Reddy's Laboratories worth $22,826,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Aquatic Capital Management LLC acquired a new stake in shares of Dr. Reddy's Laboratories during the 4th quarter valued at about $543,000. Stifel Financial Corp boosted its position in shares of Dr. Reddy's Laboratories by 592.0% during the 4th quarter. Stifel Financial Corp now owns 33,117 shares of the company's stock valued at $523,000 after acquiring an additional 28,331 shares in the last quarter. OneDigital Investment Advisors LLC lifted its holdings in Dr. Reddy's Laboratories by 413.4% during the 4th quarter. OneDigital Investment Advisors LLC now owns 17,887 shares of the company's stock valued at $282,000 after purchasing an additional 14,403 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Dr. Reddy's Laboratories by 623.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,032 shares of the company's stock valued at $48,000 after purchasing an additional 2,613 shares during the last quarter. Finally, Natixis lifted its holdings in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Natixis now owns 4,355 shares of the company's stock valued at $69,000 after purchasing an additional 3,484 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 8th.

Dr. Reddy's Laboratories Trading Up 0.3%

Shares of RDY traded up $0.05 on Friday, reaching $14.44. 1,085,237 shares of the company's stock were exchanged, compared to its average volume of 1,491,451. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $12.05 billion, a P/E ratio of 22.99 and a beta of 0.33. The business has a 50 day moving average price of $13.43 and a two-hundred day moving average price of $14.03. Dr. Reddy's Laboratories Limited has a 12 month low of $12.26 and a 12 month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. The business had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.